Diabetes is one of the most common diseases across the globe, and its prevalence is expected to rise due to the unchecked obesity epidemic. As a result, the demand for diabetes products has been going through the roof over the past decade, especially among next-generation medical devices.
Which diabetes-oriented healthcare companies are in the best position to benefit from this global trend? We asked three of our Motley Fool contributors this question, and they picked DexCom, Inc. (NASDAQ: DXCM), Insulet (NASDAQ: PODD), and Tandem Diabetes Care (NASDAQ: TNDM). Here’s why these three medtech diabetes companies should be on your radar this month.
Diabetes word on wooden letters with crystalized white sugar as frame.
Image source: Getty Images.
A medtech company with more room to run
George Budwell (DexCom, Inc.): Single-product companies with